Last reviewed · How we verify
Melatonin PR
Melatonin PR is a prolonged-release formulation of melatonin that binds to melatonin receptors to regulate circadian rhythm and promote sleep.
Melatonin PR is a prolonged-release formulation of melatonin that binds to melatonin receptors to regulate circadian rhythm and promote sleep. Used for Insomnia, Circadian rhythm sleep disorders.
At a glance
| Generic name | Melatonin PR |
|---|---|
| Also known as | Circadin, Placebo tablet of Melatonin PR |
| Sponsor | Seoul National University Hospital |
| Drug class | Melatonin receptor agonist |
| Target | MT1 and MT2 melatonin receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | FDA-approved |
Mechanism of action
Melatonin is an endogenous hormone produced by the pineal gland that regulates the sleep-wake cycle by acting on MT1 and MT2 melatonin receptors in the suprachiasmatic nucleus. The prolonged-release (PR) formulation extends melatonin availability throughout the night to maintain circadian rhythm regulation and improve sleep maintenance. This mechanism helps restore normal sleep patterns in patients with circadian rhythm disorders or insomnia.
Approved indications
- Insomnia
- Circadian rhythm sleep disorders
Common side effects
- Headache
- Dizziness
- Drowsiness
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |